• PCV55 'FAST-TRACKING' IN THE CARDIAC INTENSIVE CARE UNIT- A TRIAL-BASED ECONOMIC EVALUATION OF THREE SEDATION/ANALGESIA PROTOCOLS IN THE MANAGEMENT OF PATIENTS FOLLOWING CARDIAC SURGERY

    Nov 1, 2003, 00:00

  • PIN28 HOSPITAL MANAGEMENT OF PERTUSSIS IN GERMANY- COST PER CASE BY AGE

    Nov 1, 2003, 00:00

  • PHP29 WHERE DOES THE GERMAN HEALTH CARE SYSTEM WANT TO GO TO?

    Nov 1, 2003, 00:00

  • PPN5 ASSESSING PATIENT SATISFACTION WITH PHARMACOLOGICAL PAIN TREATMENT IN AMBULATORY PRIMARY CARE PATIENTS

    Nov 1, 2003, 00:00

  • PNM5 MANAGEMENT COSTS OF CHEST AND CNSRELATED ADVERSE EVENTS OF TRIPTANS (SEROTONIN 5-HT1B/1D AGONISTS) IN SPAIN

    Nov 1, 2003, 00:00

  • PCV24 THE MAHLER STUDY- DIFFERENCES IN RESOURCE USE FOR THE MANAGEMENT OF CHRONIC HEART FAILURE ACROSS 6 EUROPEAN COUNTRIES

    Nov 1, 2003, 00:00

  • PCV65 EVALUATING THE ECONOMIC VALUE OF SIROLIMUS-ELUTING STENT IN KOREA

    Nov 1, 2003, 00:00

  • PGS5 ECONOMIC BURDEN OF IRRITABLE BOWEL SYNDROME (IBS)- ONE YEAR RESULTS. RITMO STUDY

    Nov 1, 2003, 00:00

  • PRP16 COST-EFFECTIVENESS OF BUPROPION SR IN THE TREATMENT OF TOBACCO DEPENDENCE

    Nov 1, 2003, 00:00

  • PUK4 TREATMENT OF URINARY INCONTINENCE IN DAILY PRACTICE DOES NOT COMPLY WITH THE GUIDELINES

    Nov 1, 2003, 00:00

  • PDB2 IS THERE A GAIN WITH THE PAIN? ASSESSMENT OF THE RELATIONSHIP BETWEEN SELF-REPORTED ADHERENCE TO SELF-MONITORING OF BLOOD GLUCOSE (SMBG) AND HBA1C LEVELS AMONG TYPE 2 DIABETICS

    Nov 1, 2003, 00:00

  • PMD31 ENSURING A STANDARD USER INTERFACE FOR MODELS- MODEL-IT

    Nov 1, 2003, 00:00

  • PCN19 COST ANALYSIS OF COMPLEXED PROSTATE SPECIFIC ANTIGEN IN THE DIAGNOSIS OF PROSTATE CANCER

    Nov 1, 2003, 00:00

  • PIN26 COST OF MANAGING CHRONIC HEPATITIS B IN THE UK

    Nov 1, 2003, 00:00

  • PRP3 LOSSES IN PRODUCTIVITY DUE TO ASTHMA- A POPULATION BASED ESTIMATE

    Nov 1, 2003, 00:00

  • PCV67 AN ECONOMIC EVALUATION OF ALTEPLASE, RETEPLASE AND TENECTEPLASE IN TREATMENT OF ACUTE MI IN GREECE

    Nov 1, 2003, 00:00

  • Incorporating the Patient's Perspective into Drug Development and Communication- An Ad Hoc Task Force Report of the Patient-Reported Outcomes (PRO) Harmonization Group Meeting at the Food and Drug Administration, February 16, 2001

    Sep 1, 2003, 00:00

  • Long-Term Resource Use and Cost of Percutaneous Transluminal Coronary Angioplasty versus Stenting in the Elderly- A Retrospective Claims Data Analysis

    Sep 1, 2003, 00:00

  • When Should Functional Neuroimaging Techniques Be Used in the Diagnosis and Management of Alzheimer's Dementia? A Decision Analysis

    Sep 1, 2003, 00:00

  • Academy of Managed Care Pharmacy Format- Relevance, Rigor, Regulation, and Realism

    Sep 1, 2003, 00:00

  • The Clinical Characteristics and Impact of Laryngopharyngeal Reflux Disease on Health-Related Quality of Life

    Sep 1, 2003, 00:00

  • A Review of Selected Patient-Generated Outcome Measures and Their Application in Clinical Trials

    Sep 1, 2003, 00:00

  • The Academy of Managed Care Pharmacy Format for Formulary Submissions- An Evolving Standard—A Foundation for Managed Care Pharmacy Task Force Report

    Sep 1, 2003, 00:00

  • Validation of Health Economic Models- The Example of EVITA

    Sep 1, 2003, 00:00

  • Observations from a Hospital Executive (Decision Maker) on the Article “Long-Term Resource Use and Cost of Percutaneous Transluminal Coronary Angioplasty versus Stenting in the Elderly- A Retrospective Claims Data Analysis”

    Sep 1, 2003, 00:00

  • Methodology for Estimating Current and Future Burden of Osteoporosis in State Populations- Application to Florida in 2000 through 2025

    Sep 1, 2003, 00:00

  • Task Force Report of the Patient-Reported Outcomes Harmonization Group- Too Much Harmony, Not Enough Melody?

    Sep 1, 2003, 00:00

  • Medication Compliance Feedback and Monitoring in a Clinical Trial- Predictors and Outcomes

    Sep 1, 2003, 00:00

  • The Pediatric Quality Appraisal Questionnaire- An Instrument for Evaluation of the Pediatric Health Economics Literature

    Sep 1, 2003, 00:00

  • Cost Implications of Administering Intravenous Proton Pump Inhibitors to All Patients Presenting to the Emergency Department with Peptic Ulcer Bleeding

    Jul 1, 2003, 00:00

  • The Impact of Including Passive Benefits in Cost-Effectiveness Analysis- The Case of Automated External Defibrillators on Commercial Aircraft

    Jul 1, 2003, 00:00

  • Assessment of Respondent Acceptability of Preference Measures- Discriminatory Power of Graphic Positioning Scale versus Traditional Scaling Measures

    Jul 1, 2003, 00:00

  • Decision Makers' Needs as Capacities to Benefit

    Jul 1, 2003, 00:00

  • Cost-Effectiveness of Migraine Treatment- A Commentary

    Jul 1, 2003, 00:00

  • Seasonal versus Perennial Allergic Rhinitis- Drug and Medical Resource Use Patterns

    Jul 1, 2003, 00:00

  • A Cost-Effectiveness Analysis of Eletriptan 40 and 80 mg versus Sumatriptan 50 and 100 mg in the Acute Treatment of Migraine

    Jul 1, 2003, 00:00

  • Risk Management- Issues for Outcomes Research

    Jul 1, 2003, 00:00

  • Future Burden and Costs of Smoking-Related Disease in the Netherlands- A Dynamic Modeling Approach

    Jul 1, 2003, 00:00

  • Using Stated Preference Modeling to Forecast the Effect of Medication Attributes on Prescriptions of Alcoholism Medications

    Jul 1, 2003, 00:00

  • Do Decision Makers Really Need Health Economic Data?

    Jul 1, 2003, 00:00

  • Cost-Effectiveness Analysis of Pharmaceutical Care in a Medicare Drug Benefit Program

    Jul 1, 2003, 00:00

  • Cost-Effectiveness Analysis in Health Policy

    Jul 1, 2003, 00:00

  • Use of Pharmacoeconomics Information—Report of the ISPOR Task Force on Use of Pharmacoeconomic/Health Economic Information in Health-Care Decision Making

    Jul 1, 2003, 00:00

  • PAR4- ECONOMIC IMPLICATIONS OF NON-COMPLIANCE WITH OSTEOPOROSIS TREATMENT IN ACTUAL PRACTICE

    May 1, 2003, 00:00

  • PWM1- META-ANALYSIS OF THE EFFECTIVENESS OF MAMMOGRAPHY

    May 1, 2003, 00:00

  • PHP3- THE EFFECT OF HOSPITAL COMPLIANCE WITH THE JOINT COMMISSION ON THE ACCREDITATION OF HEALTHCARE ORGANIZATIONS (JCAHO) PERFORMANCE MEASURES AND PUBLISHED GUIDELINES ON OUTCOMES OF PATIENTS WITH HEART FAILURE

    May 1, 2003, 00:00

  • DP3- PHYSICIAN ATTITUDE TOWARD ACADEMIC DETAILING AND OTHER DRUG COST-CONTAINMENT STRATEGIES IN A STATE HEALTH INSURANCE PROGRAM

    May 1, 2003, 00:00

  • PHP21- REVIEWS OF UTAH MEDICAID HIGH UTILIZERS TO CONTROL DRUG COSTS

    May 1, 2003, 00:00

  • PCV52- WHICH STATIN? A MULTICRITERIA DECISION ANALYSIS

    May 1, 2003, 00:00

  • PNP29- CLINITRAC-A NOVEL METHOD FOR EVALUATING OUTCOME IN PARKINSON DISEASE

    May 1, 2003, 00:00

  • PIN38- COST-EFFECTIVENESS OF LOPINAVIR/RITONAVIR COMPARED TO NELFINAVIR AS FIRST-LINE ANTIRETROVIRAL THERAPY IN TREATMENTNAVE HIV PATIENTS- A MANAGED CARE PERSPECTIVE

    May 1, 2003, 00:00

  • PDB19- THE COST-EFFECTIVENESS OF TARKA FOR PREVENTING RENAL FAILURE IN TYPE 2 DIABETIC PATIENTS WITH HYPERTENSION IN THE US HEALTH CARE SETTING

    May 1, 2003, 00:00

  • PMH6- EVALUATING THE EFFECTIVENESS OF FLUOXETINE 90MG ADMINISTERED EVERY WEEK AND EVERY 2 WEEKS IN NURSING HOME RESIDENTS

    May 1, 2003, 00:00

  • PDB10- A METHODOLOGY TO IDENTIFY HIGH-RISK PATIENTS WITH DIABETES IN THE CALIFORNIA MEDICAID POPULATION (MEDI-CAL)

    May 1, 2003, 00:00

  • QL3- DIABETIC PATIENTSWILLINGNESS TO PAY FOR DIABETES EDUCATION BY PHARMACISTS- VALIDITY OF CONTINGENT VALUATION METHOD

    May 1, 2003, 00:00

  • PD4- LONGITUDINAL EXAMINATION OF OUTCOMES ASSOCIATED WITH BOTULINUM TOXIN USE IN CHILDREN WITH CEREBRAL PALSY

    May 1, 2003, 00:00

  • PESI- FACTORS INFLUENCING A POTENTIALLY INAPPROPRIATE DERMATOLOGICAL MEDICATION COMBINATION PRESCRIPTION AMONG U.S. OUTPATIENT PHYSICIANS

    May 1, 2003, 00:00

  • PDB25- COST ANALYSIS OF DIABETES TREATMENT WITH GLARGINE INSULIN OR NPH INSULIN IN SPAIN

    May 1, 2003, 00:00

  • PHP25- DOES THE PAST PREDICT THE FUTURE?

    May 1, 2003, 00:00

  • PCV32- EXCESS COSTS FOR SINGLE AGENT MEDICATION TREATMENT OF HYPERTENSION- 1999 DATA FROM THE NEWYORK STATE MEDICAID CLAIMS DATABASE

    May 1, 2003, 00:00

  • PRP5- COMPLIANCE WITH ASTHMA CONTROLLER MEDICATIONS- AN ANALYSIS OF GAPS IN CARE AND OPPORTUNITIES FOR COST REDUCTION

    May 1, 2003, 00:00

  • PMH34- COMPARISON OF OLANZAPINE VERSUS QUETIAPINE IN THE TREATMENT OF HOSPITALIZED PATIENTS WITH SCHIZOPHRENIA

    May 1, 2003, 00:00

  • PMH1- QUALITY ASSESSMENT OF META-ANALYSES OF RCTS OF PHARMACOTHERAPY IN MAJOR DEPRESSIVE DISORDER

    May 1, 2003, 00:00

  • PARI 3- COMPLIANCE WITH DRUG THERAPIES FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS

    May 1, 2003, 00:00

  • PDB5- MEDICATION COMPLIANCE IN TYPE 2 DIABETES SUBJECTS- RETROSPECTIVE DATA ANALYSIS

    May 1, 2003, 00:00

  • PCV35- COST EFFECTIVENESS ANALYSIS OF HMG-COA REDUCTASE INHIBITORS IN A MEDICAID POPULATION

    May 1, 2003, 00:00

  • PMH18- RETROSPECTIVE DRUG USE EVALUATION OF ANTIPSYCHOTIC AGENTS IN THE VETERANS ADMINISTRATION SYSTEM-A POPULATION BASED APPROACH

    May 1, 2003, 00:00

  • PRP4- THE EFFECT OF A LETTER-BASED EDUCATIONAL PROGRAM FOR PRESCRIBERS AND PHARMACISTS ON ADHERENCE TO NATIONAL ASTHMA GUIDELINES AND HEALTHCARE UTILIZATION

    May 1, 2003, 00:00

  • PHP2 3- PRESCRIBING INCENTIVE SCHEMES- DO THEY GIVE APPROPRIATE INCENTIVES FOR COST-EFFECTIVE PRESCRIBING?

    May 1, 2003, 00:00

  • PAR 14- RETROSPECTIVE ANALYSIS OF THE IMPACT OF MEDICATION NONADHERENCE ON CLINICAL OUTCOMES AND COSTS IN PATIENTS WITH OSTEOPOROSIS RECEIVING ALENDRONATE USING AN INTEGRATED PAYOR DATABASE

    May 1, 2003, 00:00

  • CV5- THE COST OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE FROM A STATE MEDICAID PROGRAM PERSPECTIVE

    May 1, 2003, 00:00

  • PMD12- PHARMACOEPIDEMIOLGY-A REVIEW OF ITS EMERGING ROLE IN OUTCOMES RESEARCH

    May 1, 2003, 00:00

  • PIN17- THE VALUE OF VACCINATING INFANTS AND CHILDREN WITH PNEUMOCOCCAL CONJUGATE VACCINE

    May 1, 2003, 00:00

  • PNP27- ASSESSING BEHAVIORAL FUNCTIONING IN ALZHEIMERS DISEASE- BENCHMARKING WITH THE BEHAVE-AD-FW

    May 1, 2003, 00:00

  • CV3- INFLUENCE OF DIABETES AND BASELINE ST-SEGMENT CHANGE STATUS ON THE COST-EFFECTIVENESS OF AN EARLY INVASIVE VS. CONSERVATIVE STRATEGY FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES-APPLICATION OF A NET-BENEFIT REGRESSION APPROACH TO DATA ...

    May 1, 2003, 00:00

  • PMH14- CLINICAL PROFILES OF SSRI USERS- FACTS EXTRACTED FROM HEALTH CARE CLAIMS DATA

    May 1, 2003, 00:00

  • PMH11- DOES THE SHORT-TERM ADMINISTRATION OF A BENZODIAZEPINE IMPROVE COMPLIANCE WITH ANTIDEPRESSANT THERAPY?

    May 1, 2003, 00:00

  • PARI I- VERIFICATION OF A DECISION ANALYTIC MODEL ASSUMPTION USING REAL WORLD PRACTICE DATA- IMPLICATIONS FORTHE COST-EFFECTIVENESS OF COX-2S

    May 1, 2003, 00:00

  • PDB3- EFFICACY OF INSULIN GLARGINE IN PATIENTS WITH TYPE 1 AND 2 DIABETES

    May 1, 2003, 00:00

  • PCV12- ACHIEVEMENT OF THE EUROPEAN ATHEROSCLEROSIS SOCIETY LDL-C TARGET BY HYPERCHOLESTEROLAEMIC PATIENTS RECEIVING ROSUVASTATIN COMPARED TO ATORVASTATIN, PRAVASTATIN OR SIMVASTATIN- AN EVIDENCE-BASED MEDICINE APPROACH

    May 1, 2003, 00:00

  • PCNIO- FEAR OF CANCER RECURRENCE AFTER TREATMENT FOR PROSTATE CANCER- DATA FROM CAPSURE

    May 1, 2003, 00:00

  • PRP24- ASSESSMENT OF THE IMPROVEMENTS IN QUALITY OF LIFE POST-LUNG TRANSPLANT- A COMPARISON OF RECIPIENTS VERSUS CANDIDATES

    May 1, 2003, 00:00

  • PNP12- A COST CONSEQUENCE ANALYSIS OF THE MANAGEMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) IN THE UK

    May 1, 2003, 00:00

  • PCHI8- ASSESSMENT OF PATIENT-REPORTED OUTCOMES AMONG PATIENTS WITH PROSTATE CANCER

    May 1, 2003, 00:00

  • PCV2- TELEMONITORS REDUCE HOSPITAL AND ER ADMISSIONS FOR HOMEBOUND CONGESTIVE HEART FAILURE (CHF) PATIENTS

    May 1, 2003, 00:00

  • PRK14- PERCEIVED RISK, VALUE AND QUALITY OF LIFE FOR PATIENTS WITH OVERACTIVE BLADDER- DEVELOPMENT OF A PERCEIVED VALUE SCALE

    May 1, 2003, 00:00

  • PIN6- IMPACT OF CHANGES IN REIMBURSEMENT POLICY ON ANTIBIOTIC RESISTANCE

    May 1, 2003, 00:00

  • PPT1- COST-EFFECTIVENESS OF RECOMBINANT HUMAN ERYTHROPOIETIN FOR PREVENTING TRANSFUSIONS IN CRITICALLY ILL PATIENTS

    May 1, 2003, 00:00

  • PRK10- COST-MINIMISATION ANALYSIS AND ACCEPTANCE OF SELF-INJECTING SUBCUTANEOUSLY R-HUEPO WITH RECOPEN FOR MANAGEMENT OF ANAEMIA IN A POPULATION OF FRENCH ADULT PATIENTS ON DIALYSIS

    May 1, 2003, 00:00

  • PMD31- COMPARING SHORT FORM 6D, STANDARD GAMBLE AND HEALTH UTILITIES INDEX MARK 2 AND MARK 3 UTILITY SCORES- RESULTS FROM TOTAL HIP ARTHROPLASTY PATIENTS

    May 1, 2003, 00:00

  • QL4- SMOKING STATUS AND HEALTH-RELATED QUALITY OF LIFE (HRQOL)- FINDINGS FROM THE BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM (BRFSS) DATA

    May 1, 2003, 00:00

  • PHP46- CHARACTERISTICS AND RISK FACTORS FOR HOSPITAL READMISSION IN MEDICAID POPULATION

    May 1, 2003, 00:00

  • AD2- MEDICATION TREATMENT PERSISTENCE OF OVERACTIVE BLADDER/URINARY INCONTINENCE PATIENTS IN A CALIFORNIA MEDICAID PROGRAM AND THE BENEFIT OF THEIR REFILL ADHERENCE ON URINARY TRACK INFECTION

    May 1, 2003, 00:00

  • PMH41- IMPACT OF DEPENDENTS DEPRESSION ON EMPLOYEE HEALTH BENEFITS COST- QUANTIFYING THE BURDEN OF CARE

    May 1, 2003, 00:00

  • PMH40- EVALUATING THE COST-EFFECTIVENESS OF ST. JOHNS WORT VERSUS FLUOXETINE FOR THE TREATMENT OF MILD TO MODERATE DEPRESSION

    May 1, 2003, 00:00

  • PMD21- AN INVESTIGATION OF PATIENT HETEROGENEITY AND THE POTENTIAL FOR BIAS IN MODELLING STUDIES-AN EXAMPLE USING A MARKOV MODEL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    May 1, 2003, 00:00

  • MHI- GENDER VARIATION IN QUALITY OF PHARMACOLOGIC CARE OF CHILDREN DIAGNOSED WITH ATTENTIONDEFICIT/HYPERACTIVITY DISORDER (ADHD)

    May 1, 2003, 00:00

  • PWM2- A MULTIDIMENSIONAL ANALYSIS OF DELIVERY-CARE

    May 1, 2003, 00:00

  • PCV3- PREDICTORS OF ADHERENCE TO ANTIHYPERTENSIVES IN A MANAGED CARE POPULATION

    May 1, 2003, 00:00

  • CV7- COST-EFFECTIVENESS OF CLOPIDOGREL IN PATIENTS WITH ISCHEMIC STROKE, MYOCARDIAL INFARCTION, OR PERIPHERAL ARTERIAL DISEASE

    May 1, 2003, 00:00

  • PHP54- EQUITY OF ACCESS TO HEALTH CARE SERVICES- AN EVIDENCE-BASED STUDY IN TAIWAN

    May 1, 2003, 00:00

  • PDB7- DIABETES RELATED DRUG UTILIZATION AND EXPENDITURES IN MEDICARE BENEFICIARIES WITH AND WITHOUT SUPPLEMENTAL PRESCRIPTION DRUG INSURANCE

    May 1, 2003, 00:00

  • AG2- RELATIONSHIP BETWEEN QUALITY OF LIFE AND COGNITIVE STATUS AMONG LONG-TERM CARE FACILITY RESIDENTS IN WEST VIRGINIA- A PILOT STUDY

    May 1, 2003, 00:00

  • PHP45- DOES REDUCING LENGTH OF POSTOPERATIVE STAY REDUCE CANCELLATION OF OPERATIONS?

    May 1, 2003, 00:00

  • PNP16- THE COMPARISON OF DIFFERENT METHODS FOR DETERMINING THE IMPACT OF MIGRAINE PROPHYLAXIS ON COSTS

    May 1, 2003, 00:00

  • PIN7- IMPACT OF THE GRIER CONSENT DECREE ON ANTIBIOTIC COSTS FOR TENNCARES MANAGED MEDICAID PROGRAM

    May 1, 2003, 00:00

  • PWM3- COMPARISON OF DIRECTTO-CONSUMER INTERVENTIONS BY A MEDICAID HEALTH PLAN TO INCREASE FOLIC ACID SUPPLEMENTATION IN WOMEN OF CHILDBEARING AGE

    May 1, 2003, 00:00

  • PCV33- COST-EFFECTIVENESS ANALYSIS OF SIMVASTATIN AND LOVASTATIN/EXTENDED-RELEASE NIACIN TO ACHIEVE LDLAND HDL GOAL USING NHANES DATA

    May 1, 2003, 00:00

  • PHP I 3- IMPROVING THE USE OF MEDICINES AND THE HEALTH KNOWLEDGE OF CONSUMERS THROUGH CIVIL EDUCATION SYSTEMS

    May 1, 2003, 00:00

  • PES19- DEVELOPMENT AND VALIDATION OF A HEALTH-RELATED QUALITY OF LIFE INSTRUMENT FOR WOMEN WITH MELASMA

    May 1, 2003, 00:00

  • PIN4- THE INFLUENCE OF PRESCRIPTION DRUG COVERAGE ON ANTIBIOTIC UTILIZATION IN ACUTE RESPIRATORY TRACT INFECTIONS- FINDINGS FROM THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)

    May 1, 2003, 00:00

  • PAR6- ECONOMIC ANALYSIS OF NOVEL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS) FOR RHEUMATOID ARTHRITIS (RA) PATIENTS IN A MANAGED CARE SETTING

    May 1, 2003, 00:00

  • PRK11- THE ECONOMICS OF PHOSPHATE BINDERS IN RENAL DIALYSIS-A TWO-STAGE STRATEGY FOR MANAGING HYPERPHOSPHATEMIA

    May 1, 2003, 00:00

  • PGS5- ECONOMIC ASSESSMENT OF DRUGS AND GI HOSPITALIZATIONS ASSOCIATED WITH APPLYING VA CRITERIA FOR PRESCRIBING NONSTEROIDAL ANTI-INFLAMMATORY AGENTS

    May 1, 2003, 00:00

  • PWM7- ECONOMIC BURDEN OF OSTEOPOROSIS, BREAST CANCER, AND CARDIOVASCULAR DISEASE AMONG WOMEN

    May 1, 2003, 00:00

  • PHP I I- A STUDY ON SAVINGS AND HEALTH-RELATED SAVING MOTIVE IN CHINESE RESIDENTS IN HONG KONG

    May 1, 2003, 00:00

  • PIN29- PHARMACOECONOMIC EVALUATION OF ANTIMICROBIAL AGENTS IN THE TREATMENT OF SEXUALLY TRANSMITTED DISEASES IN LAGOS UNIVERSITY TEACHING HOSPITAL

    May 1, 2003, 00:00

  • PMDI7- ARE PUBLISHED COST-UTILITY ANALYSES IMPROVING?

    May 1, 2003, 00:00

  • PNP7- COMPLIANCE WITH THREE-TIMES DAILY METHYLPHENIDATE IN CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

    May 1, 2003, 00:00

  • PNP6- THE USE OF DISEASE-ALTERING NEW DRUGS FOR MULTIPLE SCLEROSIS TREATMENT

    May 1, 2003, 00:00

  • PMD6- ESTIMATING THE TRAJECTORY-ADJUSTED IMPACT OF ACUTE EVENTS ON PATIENT-REPORTED OUTCOMES

    May 1, 2003, 00:00

  • PDB2- IMPROVEMENT OF HEMOGLOBIN A1C (HBA1C) TESTING AND ANALYSIS OF PARTICIPANTREPORTED RESULTS IN CAREPATTERNS FOR DIABETES PROGRAM

    May 1, 2003, 00:00

  • PGS4- EFFECT OF COMPETITION ON ANTIULCERGASTRIC-MEDICATION ACQUISITION COSTS FOR THE MEDICAID PROGRAM

    May 1, 2003, 00:00

  • PHP I 8- INCREASED HEALTHCARE UTILIZATION FOR THE ELDERLY DUE TO INAPPROPRIATE PRESCRIPTION USE

    May 1, 2003, 00:00

  • PAR2- EFFECTS OF A PRIOR AUTHORIZATION POLICY FOR CYCLOOXYGENASE-2 INHIBITORS ON HEALTH-RELATED OUTCOMES IN A MANAGED CARE MEDICAID POPULATION

    May 1, 2003, 00:00

  • PHP24- GENERIC COMPETITION IN THE PHARMACEUTICAL INDUSTRY

    May 1, 2003, 00:00

  • PCNI7- A WEIGHTED INDEX FORM OF THE FACT-L FOR USE IN ECONOMIC EVALUATION

    May 1, 2003, 00:00

  • DP4- ARE SICK PEOPLE LESS RESPONSIVE TO PRESCRIPTION BENEFIT CHANGES?

    May 1, 2003, 00:00

  • PCHI3- PHARMACOECONOMICAL ANALYSIS OF UNFRACTIONATED HEPARIN VERSUS DALTEPARIN IN PATIENTS WITH MALIGNANCIES

    May 1, 2003, 00:00

  • PMH9- INFLUENCE OF PHYSICIAN MIX AND SUPPLY ON THE DIFFUSION OF ATYPICAL ANTIPSYCHOTIC AGENTS

    May 1, 2003, 00:00

  • PRP22- IS CISATRACURIUM COST EFFECTIVE FOR NEUROMUSCULAR BLOCKADE IN THE ICU? A MARKOV COMPUTER SIMULATION STUDY

    May 1, 2003, 00:00

  • MD3- THE IMPACT OF REQUIRING A FIXED PERIOD OF ELIGIBILITY IN ECONOMIC AND EPIDEMIOLOGICAL STUDIES THAT UTILIZE LONGITUDINAL DATA

    May 1, 2003, 00:00

  • PMD4- PERFORMANCE OF TWO CONDITIONAL EXPECTATION METHODS UNDER UNOBSERVED SELECTION BIAS

    May 1, 2003, 00:00

  • PMH26- COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS IN ACUTE BIPOLAR MANIA

    May 1, 2003, 00:00

  • ASI- CHANGES IN FUNCTIONAL DISABILITY LEVELS AND MEDICAL EXPENDITURES AMONG ELDERLY PERSONS

    May 1, 2003, 00:00

  • PRK7- COMPARISON OF TACROLIMUS WITH CYCLOSPORIN IN KIDNEY TRANSPLANTATION- COST-MINIMISATION AND COSTEFFECTIVENESS ANALYSES

    May 1, 2003, 00:00

  • PCV45- HOSPITALIZARON EXPENDITURE OF ACUTE RHEUMATIC FEVER AND CHRONIC RHEUMATIC HEART DISEASE IN THE UNITED STATES

    May 1, 2003, 00:00

  • PES12- AN APPRAISAL OF VISION-RELATED QUALITY OF LIFE INSTRUMENTS

    May 1, 2003, 00:00

  • PCV51- PREDICTIVE MODELS OF HEALTH-RELATED QUALITY OF LIFE UTILIZING PATIENT REPORTED OUTCOMES DATA FROM A POPULATION WITH A HISTORY OF ACUTE CORONARY SYNDROME

    May 1, 2003, 00:00

  • PCN29- DEVELOPING A MEASUREMENT STRATEGY FOR PATIENT-REPORTED OUTCOMES- FINDINGS FROM THE NCIS CANCER OUTCOMES MEASUREMENT WORKING GROUP

    May 1, 2003, 00:00

  • PDB6- FACTORS ASSOCIATED WITH HIGH-RISK DIABETIC PATIENTS IN THE CALIFORNIA MEDICAID POPULATIONS (MEDI-CAL)

    May 1, 2003, 00:00

  • PMH16- PREVALENCE AND TRENDS IN ANTIPSYCHOTIC POLYPHARMACY AMONG MEDICAID ELIGIBLE SCHIZOPHRENIA PATIENTS IN CALIFORNIA AND GEORGIA, 1998-2000

    May 1, 2003, 00:00

  • MH2- THE RELATIONSHIP OF ASTHMA AND GENERALIZED ANXIETY DISORDER IN ADULTS

    May 1, 2003, 00:00

  • PRK3- US MEDICAL VISITS WITH DIAGNOSES PATHOGNOMONIC OF OVERACTIVE BLADDER

    May 1, 2003, 00:00

  • PMH49- PERFORMANCE OF THE SF-12 AND RAND-12 PHYSICAL AND MENTAL HEALTH SUMMARY SCORES IN PEOPLE PRACTICING MEDITATION

    May 1, 2003, 00:00

  • PMH44- UTILIZATION AND COST OF ATYPICAL ANTIPSYCHOTICS IN MEDICAID PATIENTS WITH DEPRESSION

    May 1, 2003, 00:00

  • PMD24- PROBABILISTIC SENSITIVITY ANALYSES- COMMONLY RECOMMENDED, UNCOMMONLY PERFORMED

    May 1, 2003, 00:00

  • PRP15- RELATIONSHIP BETWEEN ADHERENCE RATE AND TOTAL MEDICAL AND DRUG COSTS

    May 1, 2003, 00:00

  • PRK9- COST-EFFECTIVENESS OF TAMSULOSIN, DOXAZOSIN AND TERAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

    May 1, 2003, 00:00

  • PCHI- SECOND TREATMENT PATTERNS IN PROSTATE CANCER PATIENTS WITH BIOCHEMICAL FAILURE- DATA FROM CAPSURE

    May 1, 2003, 00:00

  • PIN49- HOW DOES PATIENT REPORT OF SYMPTOM IMPACT RELATE TO CLINICAL FUNCTIONING IN CHRONIC BRONCHITIS?

    May 1, 2003, 00:00

  • DB4- MULTI-SITE EVALUATION OF DIABETES DISEASE MANAGEMENT PROGRAMS USING THE DIABETES MANAGEMENT EVALUATION TOOL (DMET)

    May 1, 2003, 00:00

  • PNP15- COST-UTILITY ANALYSIS OF THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS WITH GLATIRAMER ACETATE OR INTERFERON BETA IN SPAIN

    May 1, 2003, 00:00

  • PCNI6- SPECIFIC CHOICES AND EXPENDITURES FOR HERBAL MEDICINES BY CANCER PATIENTS

    May 1, 2003, 00:00

  • PHP40- WORK IMPAIRMENT DUE TO CHRONIC DISEASE IN A POPULATION OF WISCONSIN SCHOOLTEACHERS

    May 1, 2003, 00:00

  • PDB114- RESOURCE UTILIZATION USING INNOLET VS. VIAL/SYRINGE FOR DAILY INSULIN INJECTION IN A SUBGROUP OF ELDERLY DIABETIC PATIENTS

    May 1, 2003, 00:00

  • PWM15- BPH- CONSEQUENCES ON THE SPOUSES SEXUALITY

    May 1, 2003, 00:00

  • PCHI5- AGREEMENT OF HEALTH UTILITIES INDEX SCORES AMONG SURVIVORS OF CANCER IN CHILDHOOD THEIR PARENTS AND THEIR DOCTORS IN URUGUAY

    May 1, 2003, 00:00

  • PHP 14- DEALIINGWITH PRESCRIPTION DRUGS- A NURSING HOME DILEMMA

    May 1, 2003, 00:00

  • PMD28- ISPOR QUALITY OF LIFE SPECIAL INTEREST GROUP-TRANSLATION AND CULTURAL ADAPTATION- DEVELOPMENT OF PRINCIPLES OF BEST PRACTICE

    May 1, 2003, 00:00

  • AD 3- PREDICTIVE MODEL OF MEDICATION ADHERENCE IN CARDIOVASCULAR DISEASE

    May 1, 2003, 00:00

  • PAR9- THE IMPLICATIONS OF RHEUMATOID ARTHRITIS IN THE UK SECONDARY CARE HEALTH CARE SYSTEM

    May 1, 2003, 00:00

  • PNP30- CHANGES IN QUALITY OF LIFE RESULTING FROM TREATMENT FOR PERSONS WITH ADVANCED PARKINSONS DISEASE- SUMANIROLE VERSUS PLACEBO

    May 1, 2003, 00:00

  • PMH15- PREDICTORS OF DURATION OF VISITS AMONG PATIENTS DIAGNOSED WITH DEPRESSION IN THE AMBULATORY MEDICAL CARE SETTINGS

    May 1, 2003, 00:00

  • PHP55- ASSOCIATION BETWEEN INCOME AND HEALTH STATUS IN THE ELDERLY CHINESE IN HONG KONG

    May 1, 2003, 00:00

  • PMH53- IMPACT OF WEIGHT GAIN ON HEALTH-RELATED QUALITY OF LIFE (HRQL) OF BIPOLAR PATIENTS

    May 1, 2003, 00:00

  • PRP1- THE IMPLEMENTATION OF NEW TREATMENT GUIDELINES IN ASTHMA BY HEALTH CARE PROVIDERS

    May 1, 2003, 00:00

  • PHP28- HEALTH INVOLVEMENT- RELATIONSHIP WITH HEALTH STATUS AND PATIENT SATISFACTION

    May 1, 2003, 00:00

  • CV4- EFFECTIVENESS OF AMLODIPINE VS. VALSARTAN UPON BLOOD PRESSURE CHANGE AND CONTROL AMONG HYPERTENSIVE ADULTS

    May 1, 2003, 00:00

  • PMH43- THE COST-UTILITY OF BUPROPION SR VERSUS SERTRALINE IN THE TREATMENT OF LATE-LIFE DEPRESSION

    May 1, 2003, 00:00

  • PHP9- FEASIBILITY OF HEALTH AND WELLNESS PROGRAMS VIA AN EMPLOYER-BASED INTRANET SITE

    May 1, 2003, 00:00

  • MD2- COMPARISON OF PATIENT SELF-REPORTED HEALTHCARE RESOURCE UTILIZATION TO ELECTRONIC RECORD DATA- LESSONS LEARNED FROM A STUDY OF HERPES ZOSTER PATIENTS

    May 1, 2003, 00:00

  • PHP47- PHYSICIAN HABITAS A DETERMINANT OF MEDICATION CHOICE

    May 1, 2003, 00:00

  • PPT7- IMPROVEMENT IN QUALITY OF LIFE AND HEALTHCARE UTILISATION DURING GROWTH HORMONE REPLACEMENT THERAPY IN HYPOPITUITARY ADULTS IN THE NETHERLANDS

    May 1, 2003, 00:00

  • PNP11- MEDICAL CARE COSTS FOR TREATING ATTENTION DEFICIT/HYPERACTIVITY DISORDER-AN EMPIRICAL STUDY BASED ON A LARGE ADMINISTRATIVE CLAIM DATA

    May 1, 2003, 00:00

  • PIN18- INFLUENZA VACCINATION IN A MALAYSIAN COMPANY-WHAT RETURN ON INVESTMENT FOR THE EMPLOYER?

    May 1, 2003, 00:00

  • PCV8- ESTIMATING POPULATION BLOOD PRESSURE CONTROL AMONG US HYPERTENSIVE PATIENTS

    May 1, 2003, 00:00

  • EP3- WORK LOSS AND HEALTHCARE UTILIZATION AMONG U.S. EMPLOYEES WITH CHRONIC NON-CANCER PAIN

    May 1, 2003, 00:00

  • PMD10- EVALUATING RETROSPECTIVE STUDY POSTERS PRESENTED AT THE ISPOR 7TH ANNUAL CONFERENCE

    May 1, 2003, 00:00

  • PMH23 PHARMACOECONOMIC COMPARISON BETWEEN TWO DRUG STRATEGIES OF TREATMENT OF ANXIETY DISORDERS- HOMEOPATHY AND PSYCHOTROPICS

    May 1, 2003, 00:00

  • PAR3- IMPACT OF THE INTRODUCTION OF THE COX-2 INHIBITORS ON THE ANALGESIC MARKET IN A PUBLIC EMPLOYEES INDEMNITY INSURANCE PROGRAM- A FIVE YEAR STUDY

    May 1, 2003, 00:00

  • PHP4I- PHARMACY REIMBURSEMENT FOR PHARMACEUTICAL CARE SERVICES IN AMBULATORY CARE SETTINGS AT US SCHOOLS OF PHARMACY

    May 1, 2003, 00:00

  • PCN6- DOSE CONVERSION OF ERYTHROPOIETIC AGENTS IN CHEMOTHERAPY-INDUCED ANEMIA-A META-ANALYSIS

    May 1, 2003, 00:00

  • PMH48- SUBJECTIVE TOLERABILITY WITH ZIPRASIDONE VS HALOPERIDOL IN ACUTE SCHIZOPHRENIA

    May 1, 2003, 00:00

  • PCV5- CLINICAL EFFECTIVENESS OF AMLODIPINE ON SYSTOLIC BLOOD PRESSURE AS MONOTHERAPYAND IN COMBINATION

    May 1, 2003, 00:00

  • PCV41- HOSPITAL COSTS AND CHARGES ATTRIBUTABLE TO THE DEVELOPMENT OF ARI/ARF AFTER CABG

    May 1, 2003, 00:00

  • PRK4- COST ANALYSIS OF NON-DIALYSIS RENAL INSUFFICIENCY (NDRI)- AN EMPLOYERS PERSPECTIVE

    May 1, 2003, 00:00

  • QL2- CLINICAL IMPROVEMENT AND RESPONSIVENESS OF PHYSICAL FUNCTION MEASURES- TREATMENT WITH CTLA4IG (BMS-188667) IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS

    May 1, 2003, 00:00

  • PGS7- COST-EFFECTIVENESS ANALYSIS OF ENDOSCOPIC SCLEROTHERAPY VERSUS LIGATION FOR THE PREVENTION OF REBLEEDING IN CHILDREN WITH OESOPHAGEAL VARICES

    May 1, 2003, 00:00

  • PCV36- COST-EFFECTIVENESS OF TREATING BY SIMVASTATIN 40 MG/DAY HIGH VASCULAR RISK PATIENTS- AN ECONOMIC EVALUATION BASED ON THE HEART PROTECTION STUDY

    May 1, 2003, 00:00

  • PDI- SUICIDE ATTEMPTS BY ADOLESCENTS- HOSPITAL RESOURCE USE AND COSTS

    May 1, 2003, 00:00

  • PCN24- DEVELOPMENT OF A PREFERENCE ELICITATION INSTRUMENT FOR USE IN PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASES IN A PROSPECTIVE RANDOMIZED CLINICAL TRIAL

    May 1, 2003, 00:00

  • PNP32- QUALITY OF LIFE (QOL) IN PATIENTS WITH PARTIAL EPILEPSY IN MOSCOW

    May 1, 2003, 00:00

  • PCV39- IMPACT OF ANEMIA ON HF HOSPITAL LENGTH OF STAY- LONGITUDINAL ANALYSIS OF A LARGE ADMINISTRATIVE DATABASE

    May 1, 2003, 00:00

  • PHP26- INAPPROPRIATE PRESCRIPTION DRUG USE AND REDUCED HEALTH STATUS FOR THE ELDERLY

    May 1, 2003, 00:00

  • PMH58- COLLEGE STUDENTS AND STRESS-WHAT IS THE CONNECTION? A HUMANISTIC OUTCOMES ASSESSMENT

    May 1, 2003, 00:00

  • PD3- RELIABILITY AND VALIDITY OF KINDL CHILDREN GENERIC HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE IN AN ASIAN SCHOOL-BASED SAMPLE

    May 1, 2003, 00:00

  • PIN50- VALIDATION OF THE HEALTH RELATED PRODUCTIVITY QUESTIONNAIRE DIARY (HRPQ-D) ON A SAMPLE OF PATIENTS WITH INFECTIOUS MONONUCLEOSIS- RESULTS FROM AN OBSERVATIONAL STUDY

    May 1, 2003, 00:00

  • PDB23- INVESTIGATOR AND SITE CHARACTERISTICS OF THE NAVIGATOR TRIAL

    May 1, 2003, 00:00

  • PCV47- PREDICTING THE SAVINGS AND RETURN ON INVESTMENT OF TOBACCO CONTROL PROGRAMS IN A MANAGED CARE SETTING USING MEDISAVE SMOKING CESSATION

    May 1, 2003, 00:00

  • PMDI5- DO DIFFERENCES AMONG COST-EFFECTIVENESS ANALYSIS GUIDELINE RECOMMENDATIONS AFFECT POLICY CONCLUSIONS?

    May 1, 2003, 00:00

  • PIN39- IMPACT OF METABOLIC ABNORMALITIES (HYPERTENSION, DIABETES MELLITUS, HYPERLIPIDEMIA) ON RESOURCE CONSUMPTION AND HEALTH CARE COSTS IN HIV-INFECTED PATIENTS

    May 1, 2003, 00:00

  • PCV10- DEFINING OUTCOMES IN STUDIES OF BLEEDING MORBIDITY ASSOCIATED WITH ANTICOAGULATION THERAPY

    May 1, 2003, 00:00

  • PHP2- THE ASSOCIATION OF PRACTICE GUIDELINES AND OTHER FACTORS WITH HOSPITAL LENGTH OF STAY (LOS) AND MORTALITY IN PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP), HEART FAILURE (HF) AND SEDATED INTENSIVE CARE PATIENTS

    May 1, 2003, 00:00

  • PDB15- COST-EFFECTIVENESS ANALYSIS OF GRAFTSKIN (APLIGRAF) AND BECAPLERMIN (REGRANEX) IN DIABETIC NEUROPATHIC FOOT ULCERS

    May 1, 2003, 00:00

  • PMH39- DEPRESSION AND FIBROMYALGIA-TREATMENT AND COST WHEN DIAGNOSED SEPARATELY OR CONCURRENTLY

    May 1, 2003, 00:00

  • PNP3- USE OF WHOS ICIDH-2 CLASSIFICATION SYSTEM IN A FUNCTIONAL ASSESSMENT OF MIGRAINEURS

    May 1, 2003, 00:00

  • PNP5- COMPARISON OF USING NDC OR ICD CODES TO SELECT PAIN PATIENTS USING DATABASE ANALYSES

    May 1, 2003, 00:00

  • PDB13- USING LINEAR REGRESSION TO APPROXIMATE RESULTS OF DECISION ANALYSIS- AN APPLICATION TO A COST COMPARISON ACROSS THREE FIRST-LINE DRUG STRATEGIES IN TYPE 2 DIABETES

    May 1, 2003, 00:00

  • PMH35- ATYPICAL ANTIPSYCHOTICS-TREATMENT PATTERNS, UTILIZATION AND COST AMONG MANAGED CARE ENROLLEES

    May 1, 2003, 00:00

  • PRK12- COMPARING SENSITIVITY TO CHANGE BETWEEN I-QOL AND SF-36 IN A POPULATION WITH URINARY INCONTINENCE

    May 1, 2003, 00:00

  • PRP13- ASSESSING THE COST IMPLICATIONS OF COMBINED PHARMACOTHERAPY IN THE LONG TERM MANAGEMENT OF ASTHMA

    May 1, 2003, 00:00

  • PGS11- INCIDENCE AND COST OF LAPAROSCOPIC CHOLECYSTECTOMY IN THE US MANAGED CARE POPULATION

    May 1, 2003, 00:00

  • PRP20- IMPROVING PHARMACEUTICAL CARE BY THE PROCUREMENT OF PALIVIZUMAB THROUGH SPECIALTY DISTRIBUTION

    May 1, 2003, 00:00

  • MH4- DRUG UTILIZATION ANALYSIS OF THE SSRI CLASS IN A MEDICAID HMO-THE FLUOXETINE EXPERIENCE

    May 1, 2003, 00:00

  • PMH28- THE IMPACT OF UNRECOGNIZED BIPOLAR DISORDERS FOR PATIENTS TREATED WITH ANTIDEPRESSANT MEDICATIONS

    May 1, 2003, 00:00

  • PMH29- ECONOMIC BURDEN OF NOT RECOGNIZING BIPOLAR DISORDER PATIENTS

    May 1, 2003, 00:00

  • PMD9- INTERNET-BASED PATIENT REGISTRIES IN COMMUNITY PRACTICE

    May 1, 2003, 00:00

  • PAR7- ASSESSMENT OF THE BURDEN OF RHEUMATOID ARTHRITIS IN FRENCH HOSPITALS-ANALYSIS OF THE PMSI DATABASE

    May 1, 2003, 00:00

  • PNP22- PREVALENCE AND MEDICAL CARE COSTS OF BACK PAIN- COMPARISON OF 1996 AND 1999 NATIONAL ESTIMATES

    May 1, 2003, 00:00

  • PIN31- THE COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS) VS. INTERFERON ALFA-2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C (CHC)

    May 1, 2003, 00:00

  • PIN15- ESTIMATING USAGE OF SELECTED ANTIINFECTIVE DRUGS IN U.S. HOSPITALS

    May 1, 2003, 00:00

  • PCV14- RACIAL VARIATION IN THE UTILIZATION OF ANTIHYPERTENSIVE MEDICATIONS- AN ANALYSIS OF 1998 MEDICAL EXPENDITURE PANEL SURVEY (MEPS) DATA

    May 1, 2003, 00:00

  • PMH5- THE IMPACT OF MIRTAZAPINE COMPARED TO NON-TCA ANTIDEPRESSANTS ON WEIGHT CHANGE IN NURSING FACILITY RESIDENTS

    May 1, 2003, 00:00

  • PRP7- USE OF LONG-TERM ASTHMA CONTROLLER MEDICATIONS BEFORE AND AFTER A HOSPITALIZATION OR EMERGENCY DEPARTMENT VISIT

    May 1, 2003, 00:00

  • PMD33- RELATIONSHIP OF QUALITY OF LIFE DOMAINS TO PREFERENCE-BASED MEASURES OF QUALITY OF LIFE

    May 1, 2003, 00:00

  • PNP4- PHYSICIAN PERCEPTIONS ON THE USE OF MEDICATIONS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER

    May 1, 2003, 00:00

  • PIN27- COST-EFFECTIVENESS OF CEFEPIME VERSUS CEFOTAXIME WHEN ADDED TO METRONIDAZOLE IN COMPLICATED INTRAABDOMINAL INFECTIONS

    May 1, 2003, 00:00

  • PIN1- ASSOCIATION BETWEEN SKIN TATTOOS AND HEPATITIS B OF 1/2000 PRIVATES AT ADISORN FORT HOSPITAL, THAILAND

    May 1, 2003, 00:00

  • PRP19- ASTHMA HEALTH CARE EXPENDITURE- THE ROLE OF CAPITATION AND MANAGED CARE

    May 1, 2003, 00:00

  • DB3- ORAL ANTIHYPERGLYCEMIC MEDICATION NON-ADHERENCE AND SUBSEQUENT HOSPITALIZARON AMONG PERSONS WITH TYPE 2 DIABETES

    May 1, 2003, 00:00

  • PHP2I- PHARMACISTS UTILIZATION AND PERCEPTIONS OF DRUG INTERACTION PROGRAM WARNINGS

    May 1, 2003, 00:00

  • PRP10- PREDICTING THE BENEFIT OF OPTIMIZING SEVERE ASTHMA MANAGEMENT IN A MANAGED CARE SETTING-A COST-BENEFIT ANALYSIS COMPARING THE COMBINATION OF FLUTICASONE PROPIONATE AND SALMETEROL (FPS) AND ZAFIRLUKAST

    May 1, 2003, 00:00

  • ND4- ARE ELDERLY PATIENTS RECEIVING APPROPRIATE ANTIEPILEPTIC DRUGS?

    May 1, 2003, 00:00

  • PCHI4- MEDICAL TREATMENT FOR CHRONIC MYELOID LEUKAEMIA (CML)-AVERAGE COST EFFECTIVENESS RATIOS OF FIRST AND SECOND LINE TREATMENT

    May 1, 2003, 00:00

  • CV2- CHOLESTEROL GOAL ATTAINMENT IN PATIENTS WITH DIABETES- EVIDENCE FROM MANAGED CARE

    May 1, 2003, 00:00

  • PIN5- RELATIONSHIP BETWEEN PRESCRIPTION USE AND ANTIMICROBIAL RESISTANCE IN THE COMMUNITY-AN EXPLORATION

    May 1, 2003, 00:00

  • PRP25- CULTURAL ADAPTATION AND VALIDATION OF CHILDHOOD ASTHMA QUESTIONNAIRE-C (CAQ-C) IN SINGAPORE

    May 1, 2003, 00:00

  • PGS12- COST-MINIMIZATION ANALYSIS OF A PHARMACIST-DIRECTED, PANTOPRAZOLE INTRAVENOUS TO ORAL DOSAGE FORM CONVERSION PROGRAM

    May 1, 2003, 00:00

  • PDB28- DEVELOPMENT OF AN INSTRUMENT TO MEASURE PATIENT EXPECTATION AND PREFERENCE FOR THE INSULIN INJECTION PEN

    May 1, 2003, 00:00

  • PMH38- A STUDY OF THE ECONOMIC BURDEN OF DEPRESSION

    May 1, 2003, 00:00

  • PMH45- COSTS AND EFFECTIVENESS OF METHADONE AND BUPRENORPHINE MAINTENANCE TREATMENTS IN WESTERN AUSTRALIA

    May 1, 2003, 00:00

  • PARI6- GASTROINTESTINAL (GI) SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE (HRQL) IN JUVENILE IDIOPATHIC ARTHRITIS (JIA)

    May 1, 2003, 00:00

  • PIN19- ROUTINE CHILDHOOD VACCINATION AGAINST INFLUENZA-AN ANALYSIS OF CLINICAL AND ECONOMIC BENEFITS

    May 1, 2003, 00:00

  • PGS3- LOW DOSE ESOMEPRAZOLE (20MG) USE IN GENERAL PRACTICE-A RETROSPECTIVE AUDIT

    May 1, 2003, 00:00

  • PMH3- THE TREATMENT CHARACTERISTICS AND OUTCOMES OF PERSONS WITH DEPRESSION AND ALCOHOLISM

    May 1, 2003, 00:00

  • PMH55- DO HEALTH EXPERIENCES IN DEPRESSION CHANGE PATIENTS VALUES?

    May 1, 2003, 00:00

  • PIN33- MEDICAL RESOURCE USE AND DIRECT MEDICAL COST OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION IN BRAZIL

    May 1, 2003, 00:00

  • PHPIO- DOCUMENTING THE RESULTS OF CLINICAL INTERVENTIONS BY PHARMACISTS IN AN AMBULATORY SETTING

    May 1, 2003, 00:00

  • NDI- COST-EFFECTIVENESS OF TOPIRAMATE AS ADJUNCTIVE TREATMENT IN REFRACTORY EPILEPSY-A PROBABILISTIC ASSESSMENT OF TREATMENT STRATEGIES

    May 1, 2003, 00:00

  • PNP34- PATIENT PREFERENCE-BASED TREATMENT RECOMMENDATIONS FOR ENDOMETRIOSIS PAIN- CHOICE OF METHOD MATTERS

    May 1, 2003, 00:00

  • ND3- ECONOMIC ANALYSIS OF ACUTE MIGRAINE THERAPY UTILIZATION WITHIN THE WISCONSIN STATE MEDICAID POPULATION

    May 1, 2003, 00:00

  • PGS8- UTILIZATION IMPACT OF PROTON PUMP INHIBITOR ON TREATMET COSTS FOR GASTROESOPHAGEAL REFLUX DISEASE USING HEALTH CARE CLAIMS DATA IN TAIWAN

    May 1, 2003, 00:00

  • PNP8- A MARKOV MODEL OF TREATMENT OF NEWLY DIAGNOSED EPILEPSY IN THE UK-AN ASSESSMENT OF COST-EFFECTIVENESS OF TOPIRAMATE

    May 1, 2003, 00:00

  • PWM13- PREDICTORS OF RESPONSE TO ERECTILE DYSFUNCTION TREATMENT AT 12 MONTHS- RESULTS FROM THE EXCEED DATABASE

    May 1, 2003, 00:00

  • PWM9- ECONOMIC IMPACT OF SILDENAFIL CITRATE ON A PHARMACY BUDGET

    May 1, 2003, 00:00

  • PAR I 8- PREVALENCE OF DEPRESSIVE SYMPTOMATOLOGY AND ITS RELATIONSHIP TO HRQOL IN ARTHRITIS- A WEB-BASED HEALTH STATUS SURVEY

    May 1, 2003, 00:00

  • PES17- IMPACT OF HYDROTHERAPY CARES ON THE QUALITY OF LIFE OF PATIENTS SUFFERING FROM SKIN DISEASES

    May 1, 2003, 00:00

  • PCV25- AN INVESTIGATION OF THE CARE NEEDS AFTER ACUTE ISCHEMIC STROKE- AN ANALYSIS OF THE DATA COLLECTED IN THE ERLANGEN STROKE PROJECT

    May 1, 2003, 00:00

  • PPT2- COST ANALYSIS OF PROPHYLACTIC TREATMENT OF CHILDREN WITH SEVERE HEMOPHILIA A IN CANADA

    May 1, 2003, 00:00

  • PCN9- PATIENT CHARACTERISTICS IMPACTING LENGTH OF STAY AND IN-PATIENT CHARGES AMONG US COLORECTAL CANCER PATIENTS

    May 1, 2003, 00:00

  • PIN14- POLICY EVALUATION FOR INFLUENZA VACCINATION OF ELDERLY IN JAPAN

    May 1, 2003, 00:00

  • PMH51- IMPACT OF COMORBID DIABETES ON FUNCTIONING IN SCHIZOPHRENIA

    May 1, 2003, 00:00

  • PES18- PSORIASIS AND QUALITY OF LIFE- SPANISH RESULTS

    May 1, 2003, 00:00

  • PWM10- COST OF ACCESS BY FORMULARY TYPE- A CASE STUDY OF SILDENAFIL CITRATE IN A LARGE MANAGED CARE ORGANIZATION

    May 1, 2003, 00:00

  • DP2- ECONOMIC IMPACT OF PROZAC PATENT EXPIRATION AND THE 180-DAY GENERIC FLUOXETINE EXCLUSIVITY IN A PUBLICLY-FINANCED PRESCRIPTION PROGRAM

    May 1, 2003, 00:00

  • AD4- A TIME-VARYING SURVIVAL MODEL FOR THE ASSOCIATION OF ADHERENCE WITH HMG-COA INHIBITORS TO THE RISK OF ADVERSE EVENTS

    May 1, 2003, 00:00

  • PCV7- TREATMENT OF PRIMARY PULMONARY HYPERTENSION (PPH)- A COST-UTILITY ANALYSIS

    May 1, 2003, 00:00

  • EP4- ALLERGY PREVALENCE, COST AND PRODUCTIVITY LOSS IN AN INSURED EMPLOYEE POPULATION

    May 1, 2003, 00:00

  • PRK1- COMPARISON OF DIRECT HEALTH-CARE COST, HOSPITAL UTILIZATION AND MEDICATION PERSISTENCE BETWEEN EXTENDED RELEASE FORMS (ER) OF TOLTERODINE AND OXYBUTYNIN IN OVERACTIVE BLADDER/URINARY INCONTINENCE PATIENTS

    May 1, 2003, 00:00

  • PNP17- THE ECONOMIC BURDEN OF MIGRAINE AND COMORBID MENTAL CONDITIONS- RESULTS FROM A CASE-CONTROL STUDY

    May 1, 2003, 00:00

  • PCH4- ESTIMATING LIFE LOST DUE TO CANCER IN THE US-A COMPARISON OF LONGITUDINAL AND CROSS-SECTIONAL MEASURES

    May 1, 2003, 00:00

  • DPI- RELATIONSHIP BETWEEN DIRECT-TO-CONSUMER ADVERTISING AND PRODUCT INNOVATIVENESS

    May 1, 2003, 00:00

  • PMH17- USE OF SEDATIVE/HYPNOTIC AGENTS BY AN ELDERLY AMBULATORY POPULATION

    May 1, 2003, 00:00

  • PDB9- IMPACT OF AGE, GENDER, AND OUT-OFPOCKET COSTS ON THE TIME TO DISCONTINUATION OF ORAL ANTI-DIABETIC AGENTS AMONG PATIENTS WITH TYPE 2 DIABETES

    May 1, 2003, 00:00

  • PMH54- MENTAL HEALTH COMORBIDITY PREVALENCE, PATTERNS, AND IMPACT ON QUALITY OF LIFE AMONG GULF WAR VETERANS

    May 1, 2003, 00:00

  • PHP27- HEALTH RELATED QUALITY OF LIFE AMONG PRESCRIPTION DRUG USERS IN SWEDEN-AN EPIDEMIOLOGICAL SURVEY

    May 1, 2003, 00:00

  • PRP16- RESOURCE UTILIZATION (HOSPITAL AND PHYSICIAN COST/VISITS) AFTER INTRODUCTION OF THE NEW TREATMENT GUIDELINES IN ASTHMA (1997)

    May 1, 2003, 00:00

  • PES6- ECONOMIC EVALUATION OF PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR SMALL SUBFOVEAL CNV LESIONS-THE CASE OF AUSTRALIA

    May 1, 2003, 00:00

  • PES14- IMPACT OF HYDROTHERAPY CARE ON THE QUALITY OF LIFE OF CHILDREN

    May 1, 2003, 00:00

  • PARI9- A UTILITY VALUATION STUDY ASSESSING TREATMENT OUTCOMES IN OSTEOARTHRITIS

    May 1, 2003, 00:00

  • QLI- QUALITY OF LIFE, UTILITY, AND WILLINGNESS TO PAY IN PATIENTS WITH DIABETES

    May 1, 2003, 00:00

  • PIN21- COST-EFFECTIVENESS OF SELECTED INTERVENTIONS TO REDUCE THE BURDEN OF CHILDHOOD PNEUMONIA AND DIARRHEA- A STANDARDISED ANALYSIS

    May 1, 2003, 00:00

  • PRP18- PHARMACOECONOMIC COMPARISON BETWEEN TWO DRUG STRATEGIES OF TREATMENT OF RECURRENT ACUTE RHINOPHARYNGITIS IN 18-MONTH-OLD TO 4-YEAR-OLD CHILDREN- HOMEOPATHY AND ANTIBIOTICS

    May 1, 2003, 00:00

  • PDB26- EVALUATION OF QUALITY OF LIFE IN PATIENTS WITH NEUROPATHY USING THE NORFOLK QUALITY OF LIFE (QOL) TOOL

    May 1, 2003, 00:00

  • PCV38- A COST AND COST-EFFECTIVENESS (CE) ANALYSIS OF ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORTRANDOLAPRIL IN THE TREATMENT OF POST INFARCTION IN THE US

    May 1, 2003, 00:00

  • PMH12- ASSESSING THE RELATIONSHIP OF GENERALIZED ANXIETY DISORDER AND PEPTIC ULCER DISEASE

    May 1, 2003, 00:00

  • PRK13- DEVELOPMENT OF A QUESTIONNAIRE TO ASSESS QUALITY OF CARE IN DUTCH DIALYSIS CENTERS

    May 1, 2003, 00:00

  • PNP28- STUDY OF THE QUALITY OF LIFE IN PARKINSONS DISEASE PATIENTS IN RUSSIA

    May 1, 2003, 00:00

  • PCN21- DIFFERENCES IN HUSBAND/WIFE PREFERENCES AND UTILITIES FOR PROSTATE CANCER THERAPIES

    May 1, 2003, 00:00

  • PHP7- CRITICAL EVALUATION OF INTERVENTIONS TO ENHANCE PATIENT COMPLIANCE WITH CHRONIC MEDICATIONS

    May 1, 2003, 00:00

  • PDB1- RELATION BETWEEN MEDICATION COMPLIANCE AND GLUCOSE CONTROL IN PATIENTS WITH TYPE 2 DIABETES

    May 1, 2003, 00:00

  • PRP9- THE NET COST OF ASTHMA TO NORTH CAROLINA (NC) MEDICAID AND IDENTIFICATION OF FACTORS DRIVING COSTS IN AN ASTHMATIC POPULATION

    May 1, 2003, 00:00

  • PMH47- VALIDATION OF ENGLISH AND CHINESE VERSIONS OF THE SQLS, SF-36 AND HUI3 IN PATIENTS WITH SCHIZOPHRENIA IN SINGAPORE

    May 1, 2003, 00:00

  • PCN2 3- HEALTH-RELATED QUALITY OF LIFE BURDEN OF HEAD AND NECK CANCER

    May 1, 2003, 00:00

  • PNP33- HOW DOES AN 11-POINT PAIN SCALE RELATE TO PREFERENCE ESTIMATES IN PATIENTS WITH CHRONIC PAIN AND CAN IT BE USED TO PREDICT PREFERENCES?

    May 1, 2003, 00:00

  • PRP11- CHANGES IN ASTHMA-RELATED HEALTHCARE UTILIZATION AND COSTS AFTER THE ADDITION OF SALMETEROL TO A MEDICAID POPULATION

    May 1, 2003, 00:00

  • AC4- INAPPROPRIATE DRUG PRESCRIBING IN OUTPATIENT CARE FOR THE ELDERLY-THE CASE OF POTENTIALLY HARMFUL DRUG-DRUG AND DRUG-DISEASE COMBINATIONS

    May 1, 2003, 00:00

  • CV8- CURRENT PATTERNS OF CARE AND TREATMENT COSTS ASSOCIATED WITH VENOUS THROMBOEMBOLIC DISEASE

    May 1, 2003, 00:00

  • PGS1- IMPACT OF RISK MODELING INFORMATION ON THE PRESCRIBING OF COX-2 INHIBITOR AGENTS

    May 1, 2003, 00:00

  • PRP3- CLINICAL EFFECTIVENESS OF BUDESONIDE AND FORMOTEROL IN A SINGLE INHALER IN PATIENTS WITH ASTHMA-AN AUDIT IN UK GENERAL PRACTICE

    May 1, 2003, 00:00

  • PWM5- FEASIBILITY OF SIMPLIFYING COMPLEX DECISION TREES VIA LINEAR REGRESSION ANALYSIS-AN APPLICATION TO COST-EFFECTIVENESS ANALYSIS OF HORMONE THERAPY FOR MENOPAUSAL SYMPTOMS

    May 1, 2003, 00:00

  • PIN40- THE COST EFFECTIVENESS OF IMPROVED ADHERENCE TO ANTIRETROVIRAL TREATMENT

    May 1, 2003, 00:00

  • PIN36- COST-SAVINGS OF AN IV TO PO ACYCLOVIR SWITCH IN A STANDARDIZED HSV PROPHYLAXIS PROTOCOL ON A BMT UNIT

    May 1, 2003, 00:00

  • PIN46- HIV/AIDS PATIENTS- EXPERIENCES WITH HOSPITALIZATION

    May 1, 2003, 00:00

  • PMH27- EFFECTS OF PATIENTS WITH BIPOLAR, SCHIZOPHRENIC, AND MAJOR DEPRESSIVE DISORDERS ON THE MENTAL AND OTHER HEALTHCARE EXPENSES OF FAMILY MEMBERS

    May 1, 2003, 00:00

  • PMH33- OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA-A MENTAL HEALTH COST COMPARISON IN A MANAGED CARE SETTING

    May 1, 2003, 00:00

  • PIN44- THE COST OF SEVERE SEPSIS AT A TERTIARY CARE TEACHING INSTITUTION

    May 1, 2003, 00:00

  • PNP20- COST UTILITY ANALYSIS OF IMMUNOGLOBULINS (IVIG) VERSUS PLASMA EXCHANGE (PE) FOR THE TREATMENT OF GUILLAIN BARRE SYNDROME (GBS)

    May 1, 2003, 00:00

  • PRP21- THE ECONOMIC IMPACT OF HOMEOPATHIC MANAGEMENT- THE FRENCH EXAMPLE

    May 1, 2003, 00:00

  • PES8- BURDEN OF ILLNESS OF ECZEMA IN CANADA

    May 1, 2003, 00:00

  • PHP49- HOSPITALIZATIONS RELATED TO DOMESTIC VIOLENCE- CHILD ABUSE BY A PARENT OR GUARDIAN

    May 1, 2003, 00:00

  • PGS6- THE COST-EFFECTIVENESS OF ALTERNATIVE STRATEGIES IN THE MANAGEMENT OF PATIENTS WITH UNINVESTIGATED DYSPEPSIA (UD)- COMPARING THE CANDYS APPROACH TO EMPIRICAL ANTISECRETORY THERAPY AND PROMPT ENDOSCOPY

    May 1, 2003, 00:00

  • PHP34- IMPROVING OUTCOMES THROUGH ACCESS TO CRITIQUED ECONOMIC EVALUATIONS-THE NHS ECONOMIC EVALUATION DATABASE WITHIN THE HTA REVIEW PROCESS

    May 1, 2003, 00:00

  • PMD13- OPTIMIZING CLINICAL EFFECTIVENESS THROUGH ACTUARIAL MODELING IN HOSPITALS

    May 1, 2003, 00:00

  • PHP5- CORRELATIONS BETWEEN A STAGE OF CHANGE MEASURE AND FOUR VALIDATED MEASURES OF MEDICATION COMPLIANCE

    May 1, 2003, 00:00

  • PCH3- PERFORMANCE OF THE MC-PEEK-SCORE FOR SURGICAL OUTCOME

    May 1, 2003, 00:00

  • PHP IO- IMPACT OF RISK DISCLOSURES IN DIRECT-TO-CONSUMER ADVERTISING ON ELDERLY CONSUMERS BEHAVIORAL INTENT

    May 1, 2003, 00:00

  • PCV34- DETERMINANTS OF COST EFFECTIVENESS IN CLINICAL GUIDELINES FOR CARDIOVASCULAR PROPHYLAXIS WITH STATINS

    May 1, 2003, 00:00

  • PNP23- COST-EFFECTIVENESS OF DRUG THERAPY FOR POSTHERPETIC NEURALGIA

    May 1, 2003, 00:00

  • PMH31- PATTERNS OF TREATMENT AMONG BIPOLAR DISORDER PATIENTS TREATED WITH ANTIDEPRESSANTS

    May 1, 2003, 00:00

  • PCV4- THE EFFECT OF STATIN DOSE ON ATTAINMENT OF TARGET LDL-C LEVELS

    May 1, 2003, 00:00

  • PIN16- ASSESSMENT OF ECONOMIC MODELS OF ANTIRETROVIRAL THERAPIES IN HIV/AIDS

    May 1, 2003, 00:00

  • PRK15- DISEASE-SPECIFIC PATIENT-REPORTED OUTCOME MEASURES IN URINARY INCONTINENCE

    May 1, 2003, 00:00

  • PIN12- IMPLICATIONS OF APPLYING DIFFERENT NATIONAL GUIDELINES ADDRESSING SURGICAL ANTIBIOTIC PROPHYLAXIS- A CROSS SECTIONAL STUDY OF 386 PATIENTS UNDERGOING TOTAL HIP REPLACEMENT SURGERY

    May 1, 2003, 00:00

  • Abstracts Index

    May 1, 2003, 00:00

  • PHP33- RISK SHARING IN A STATE FUNDED HEALTH SERVICE- OUTCOMES GUARANTEE PROJECT

    May 1, 2003, 00:00

  • PIN11- DYSLIPIDEMIA MANAGEMENT AMONG HIVINFECTED PATIENTS TREATED WITH PROTEASE INHIBITORS (PI)

    May 1, 2003, 00:00

  • PRK2- FACTORS ASSOCIATED WITH DIALYSIS TREATMENT COSTS AMONG MEDICARE ENROLEES

    May 1, 2003, 00:00

  • PPT6- HEMOPHILIA ECONOMIC MODEL OF OUTCOMES- CASE STUDY

    May 1, 2003, 00:00

  • PHP I 6- POLISH GUIDELINES FOR COSTING IN PHARMACOECONOMIC EVALUATION IN COMPARISON TO EXISTING GUIDANCE FOR COSTING IN OTHER COUNTRIES

    May 1, 2003, 00:00

  • PGS13- DIFFERENCES BETWEN ELDERLY AND YOUNGER ADULTS IN THE EPIDEMIOLOGY AND TREATMENT OF SYMPTOMATIC GERD AND NOCTURNAL GERD

    May 1, 2003, 00:00

  • PDB18- ESTIMATING THE COST-EFFECTIVENESS OF REPAGLINIDE PLUS METFORMIN VS. NATEGLINIDE PLUS METFORMIN OVER A 30-YEAR PERIOD

    May 1, 2003, 00:00

  • PDB24- FACTORS INFLUENCING THE DIAGNOSTIC TESTS PRESCRIBING FOR TYPE 2 DIABETES IN AMBULATORY PATIENTS

    May 1, 2003, 00:00

  • PIN47- SIDE EFFECTS AND THEIR BURDEN ON HIV-INFECTED PATIENTS

    May 1, 2003, 00:00

  • PMH21- REINFORCE AND ADVOCATE COMMUNITY AND SCHOOL EDUCATIONAL PROGRAM IN SAFETY USE OF MEDICATION AND PREVENTION OF DRUG ABUSE IN CENTRAL OF TAIWAN

    May 1, 2003, 00:00

  • PMH36- ECONOMIC EVALUATION OF ATYPICAL ANTIPSYCHOTICS WITHIN THE WISCONSIN MEDICAID PROGRAM

    May 1, 2003, 00:00

  • PES9- A BASELINE ASSESSMENT OF THE VALIDITY OF THE 39-ITEM NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE IN GERMAN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION

    May 1, 2003, 00:00

  • PAR I7- COMPARING SHORT FORM AND RAND PHYSICAL AND MENTAL HEALTH SUMMARY SCORES- RESULTS FROM TOTAL HIP ARTHROPLASTYAND HIGH-RISK PRIMARY-CARE PATIENTS

    May 1, 2003, 00:00

  • PCV6- A REVIEW OF THE PHARMACOTHERAPEUTIC MANAGEMENT OF PULMONARY ARTERIAL HYPERTENSION

    May 1, 2003, 00:00

  • PCV44- EVALUATION ON THE COST OF MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN A LOCAL PUBLIC HOSPITAL IN HONG KONG

    May 1, 2003, 00:00

  • PIN24- COST EFFECTIVENESS ANALYSIS OF LINEZOLID VS. TEICOPLANIN FOR THE TREATMENT OF SERIOUS GRAM-POSITIVE BACTERIAL INFECTIONS IN A MULTINATIONAL RANDOMIZED TRIAL

    May 1, 2003, 00:00

  • PIN10- THE ALLOCATION OF HIV PREVENTION FUNDS

    May 1, 2003, 00:00

  • PES11- QUALITY OF LIFE IN PATIENTS WITH AGERELATED MACULAR DEGENERATION-A CONJOINT ANALYSIS APPROACH

    May 1, 2003, 00:00

  • PDB16- COST OF TYPE 2 DIABETES CARE IN AUSTRALIA-THE DIABCOST STUDY

    May 1, 2003, 00:00

  • PNP14- COST OF MULTIPLE SCLEROSIS BY LEVEL OF DISABILITY

    May 1, 2003, 00:00

  • PCV43- PREDICTING THE BURDEN OF CONGESTIVE HEART FAILURE (CHF) IN A MANAGED CARE SETTING- A NEW MODEL TO PREDICT OUTCOMES AND EVALUATE THE COST-BENEFIT OF CHF MANAGEMENT

    May 1, 2003, 00:00

  • PCV17- RELATIONSHIP BETWEEN PATIENT BELIEFS ABOUT MEDICATION AND SELF-REPORTED MEDICATION ADHERENCE SIX MONTHS AFTER DISCHARGE FOR ACUTE CORONARY SYNDROMES

    May 1, 2003, 00:00

  • PHP29- PREDICTIVE FACTORS OF INPATIENT DRUG COSTS IN A MOTHER-CHILD TEACHING HOSPITAL

    May 1, 2003, 00:00

  • PCN7- CERVICAL CANCER SCREENING IN THE PHILIPPINE SETTING-A COST-EFFECTIVENESS ANALYSIS

    May 1, 2003, 00:00

  • PIN25- A COST-EFFECTIVENESS ANALYSIS OF BACTERIAL ENDOCARDITIS PROPHYLAXIS FOR FEBRILE CHILDREN WITH CARDIAC LESIONS

    May 1, 2003, 00:00

  • PHP4- BIAS IN CATEGORICAL MEDICATION COMPLIANCE ASSESSMENT

    May 1, 2003, 00:00

  • PRP8- COMPARISON OF THE ECONOMIC IMPACT OF MONTELUKAST AND INHALED CORTICOSTEROID AGENTS ON ALLERGIC RHINITIS-RELATED UTILIZATION IN PATIENTS WITH ASTHMA

    May 1, 2003, 00:00

  • PMH22 A NATIONAL ESTIMATE OF INDIRECT COSTS ASSOCIATED WITH ANXIETY DISORDERS

    May 1, 2003, 00:00

  • PIN34- DIRECT MEDICAL COSTS ASSOCIATED WITH HEPATITIS B VIRUS (HBV) INFECTION IN THE UNITED STATES

    May 1, 2003, 00:00

  • PIN41- PERTUSSIS VACCINATION IN ADOLESCENTS- COSTS AND CONSEQUENCES OF NEW PROPOSED VACCINATION PROGRAMMES IN CANADA

    May 1, 2003, 00:00

  • PES13- COMPARING THE QUALITY OF LIFE EFFECTS OF PRIMARY FOCAL HYPERHIDROSIS TO OTHER DERMATOLOGICAL CONDITIONS AS ASSESSED BY THE DERMATOLOGY LIFE QUALITY INDEX (DLQI)

    May 1, 2003, 00:00

  • PIN51- ASSESSING DISEASE-SPECIFIC UTILITY IN RECURRENT GENITAL HERPES (RGH)

    May 1, 2003, 00:00

  • PHP41- EVALUATION OF AN INTEGRATED WORKERS COMPENSATION/HEALTH INSURANCE PHARMACY BENEFIT PROGRAM- SATISFACTION, HEALTH OUTCOMES AND POTENTIAL COST SAVINGS

    May 1, 2003, 00:00

  • PRK6- A RETROSPECTIVE CLAIMS ANALYSIS OF THE DIRECT COSTS OF STRESS URINARY INCONTINENCE

    May 1, 2003, 00:00

  • MH3- EVALUATING THE ECONOMIC CONSEQUENCES OF EARLY SSRI DROP-OUTS IN DEPRESSION

    May 1, 2003, 00:00

  • PMH46- COST CONSEQUENCES OF APPLYING APPROPRIATE USE EDITS TO SELECT HYPNOTIC AGENTS-A RETROSPECTIVE COMPARATIVE ANALYSIS

    May 1, 2003, 00:00

  • PDB22- THE DIRECT COST OF DIABETES TYPE 2 IN POLAND-PRELIMINARY DATA FROM CODIP STUDY

    May 1, 2003, 00:00

  • PHP30- RATES OF CONTINUATION OF NON FORMULARY MEDICATIONS FOR CHRONIC DISEASE SUFFERERS IN MULTI-TIERED PHARMACY BENEFIT PLANS

    May 1, 2003, 00:00

  • PMH8- PHARMACOLOGIC TREATMENT OF HOSPITALIZED PATIENTS WITH BIPOLAR DISORDER

    May 1, 2003, 00:00

  • PARI2- COST-EFFECTIVENESS OF RALOXIFENE FOR THE PREVENTION OF OSTEOPOROTIC FRACTURES IN AUSTRALIA

    May 1, 2003, 00:00

  • PWM16- BENIGN PROSTATIC HYPERPLASIA- RECOGNITION OF THE CONSEQUENCES OF THE PATHOLOGY FOR THE SPOUSE

    May 1, 2003, 00:00

  • PHP I- COMPLIANCE WITH DRUG TREATMENT IN SWEDEN- AN EPIDEMIOLOGICAL STUDY

    May 1, 2003, 00:00

  • PMH57- PSORIASIS, QUALITY OF LIFE AND DEPRESSIVE SYMPTOMATOLOGY-FRENCH RESULTS

    May 1, 2003, 00:00

  • PCV29- HEALTH SERVICE UTILIZATION, COSTS AND OUTCOMES OF PATIENTS WHO USED DIFFERENT TYPES OF CALCIUM CHANNEL BLOCKERS FOR HYPERTENSION

    May 1, 2003, 00:00

  • PMH2- A META-ANALYSIS AND COMMON COMPARATOR ANALYSIS OF OLANZAPINE VERSUS ZIPRASIDONE AND ARIPIPRAZOLE

    May 1, 2003, 00:00

  • PNP9- COST-EFFECTIVENESS ANALYSIS OF PRAMIPEXOLE IN EARLY PARKINSONS DISEASE

    May 1, 2003, 00:00

  • PCV18- A CONFIRMATORY FACTOR ANALYSIS EVALUATION OF THE CORONARY HEART DISEASE RISK FACTORS OF METABOLIC SYNDROME AND THE EFFECTIVENESS OF THE CURRENT ATP III GUIDELINES FOR IDENTIFICATION

    May 1, 2003, 00:00

  • PHP52- VARIATIONS IN UTILIZATION RATES, CLINICAL TRIGGERS AND OUTCOMES OF X-RAYS IN A DEVELOPING COUNTRY

    May 1, 2003, 00:00

  • PMD11- BEST PRACTICES- EVALUATING MODELING RESEARCH AT ISPOR USING BMJAND ISPOR GUIDELINES

    May 1, 2003, 00:00

  • PCV30- ECONOMIC EVALUATION OF LOSARTAN COMPARED WITH ATENOLOL IN THE TREATMENT OF HYPERTENSION WITH LEFT VENTRICULAR HYPERTROPHY- A COST-MINIMIZATION ANALYISIS BASED ON LIFE STUDY

    May 1, 2003, 00:00

  • PMH56- QUALITY OF LIFE TRAJECTORIES AMONG MASSACHUSETTS ADULTS WITH SUBSTANCE USE DISORDERS

    May 1, 2003, 00:00

  • PCV11- EFFECTIVENESS OF CLINICAL PATHWAYS FOR PATIENTS WITH HEART FAILURE

    May 1, 2003, 00:00

  • PRK5- ANALYSIS OF COMORBIDITY, HOSPITAL UTILIZATION AND COST OF OVERACTIVE BLADDER IN A CALIFORNIA MEDICAID PROGRAM-A CASE-CONTROL STUDY

    May 1, 2003, 00:00

  • PIN30- HOSPITALIZATION EXPENDITURE OF STREPTOCOCCUS PYOGENES-ASSOCIATED CELLULITIS IN THE UNITED STATES

    May 1, 2003, 00:00

  • DBI- IMPACT OF PARTICIPANT COST-SHARE ON COMPLIANCE RATES IN PARTICIPANTS WITH DIABETES

    May 1, 2003, 00:00

  • PCV21- TREATMENT PATTERNS AMONG NEWLY DIAGNOSED CORONARY HEART DISEASE PATIENTS- CORRELATES OF LIPID MANAGEMENT

    May 1, 2003, 00:00

  • PARI- USE OF ALTERNATIVE THERAPY, QUALITY OF LIFE AND HEALTHCARE SPENDING IN CHINESE PATIENTS WITH OSTEOARTHRITIS

    May 1, 2003, 00:00

  • PRP14- RATES OF ASTHMA-RELATED MEDICAL AND PRESCRIPTION RESOURCE UTILIZATION AND COSTS IN A MEDICAID POPULATION

    May 1, 2003, 00:00

  • PMH50- COMORBID DIABETES AND SCHIZOPHRENIA- IMPACT ON HEALTHCARE RESOURCE USE

    May 1, 2003, 00:00

  • PMD25- INCREASING PUBMEDYIELD FOR PHARMACOECONOMIC RESEARCH USING ITERATIVE SEARCH STRATEGIES

    May 1, 2003, 00:00

  • PAR8- COST BURDEN OF HIP AND KNEE REPLACEMENTS IN OHIO AND IN THE UNITED STATES- ESTIMATED FROM THE NATIONAL HOSPITAL DISCHARGE SURVEY 2000

    May 1, 2003, 00:00

  • PES7- COST-EFFECTIVENESS ANALYSIS OF CATARACT CONTROL IN 14 WORLD REGIONS

    May 1, 2003, 00:00

  • PPT9- HEALTHCARE CONSUMPTION, QOL, AND PATIENT-REPORTED OUTCOMES DURING GH REPLACEMENT IN HYPOPITUITARY ADULTS- RESULTS FROM THE GERMAN KIMS COHORT

    May 1, 2003, 00:00

  • PWM4- EVALUATION OF A PHARMACEUTICAL PATIENT ASSISTANCE PROGRAM-THE NORPLANT REMOVAL PROGRAM

    May 1, 2003, 00:00

  • PMDI9- COMMUNITY OR PATIENT PREFERENCES FOR COST-UTILITY ANALYSES- DOES IT MATTER?

    May 1, 2003, 00:00

  • PWM12- LONGITUDINAL DIFFERENCES IN PSYCHOLOGICAL ADJUSTMENT FOR MEN WITH ERECTILE DYSFUNCTION- RESULTS FROM EXCEED

    May 1, 2003, 00:00

  • PES10- PATIENT REPORTED OUTCOMES AND ECONOMIC IMPLICATIONS OF A REFORMULATION TO IMPROVE BRIMONIDINE 0.2

    May 1, 2003, 00:00

  • PMDI- A NEW METHOD FOR TIME ADJUSTMENT OF THE NUMBER NEEDED TO TREAT REGARDING VARIABLE RELATIVE RISK REDUCTION

    May 1, 2003, 00:00

  • PES3- A MODEL-BASED PHARMACOECONOMIC ANALYSIS OF BRIMONIDINE TARTATE 0.2 AS AN ADJUNCTIVE THERAPY TO BETA-BLOCKERS IN THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION IN ADULT PATIENTS IN NORWAY

    May 1, 2003, 00:00

  • PDB12- A COMPARISON OF TWO METHODS FOR ESTIMATING HEALTH CARE COSTS OF DIABETES

    May 1, 2003, 00:00

  • PIN28- ESTIMATED COST SAVINGS OF DISCONTINUING SECONDARY PROPHYLAXIS FOR OPPORTUNISTIC INFECTIONS AFTER IMMUNOLOGICAL RECONSTITUTION WITH HAART

    May 1, 2003, 00:00

  • PIN45- THE COST EFFECTIVENESS OF PI BASED THERAPY WITH NELFINIVIR (NLF) COMPARED TO RITONAVIR (RTV) FOR PATIENTS WITH HIV/AIDS

    May 1, 2003, 00:00

  • PHP39- DOES POOR HEALTH STATUS LEAD TO LOWER INCOME PRODUCTIVITY?

    May 1, 2003, 00:00

  • PHP5I- MEDICAL DEVICE PROBLEMS IN INTENSIVE CARE UNITS- DETECTION, DANGERS, AND DIVERSITY OF TYPES

    May 1, 2003, 00:00
  • «
  • 171
  • 172
  • 173
  • 174 (current)
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • »